FUJITA HEALTH UNIVERSITY
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1968-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.fujita-hu.ac.jp
Clinical Trials
148
Active:0
Completed:63
Trial Phases
5 Phases
Phase 1:2
Phase 2:5
Phase 3:1
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (145 trials with phase data)• Click on a phase to view related trials
Not Applicable
133 (91.7%)Phase 2
5 (3.4%)Phase 4
4 (2.8%)Phase 1
2 (1.4%)Phase 3
1 (0.7%)A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease
Not Applicable
Recruiting
- Conditions
- Parkinson's Disease (PD)
- Interventions
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Fujita Health University
- Target Recruit Count
- 24
- Registration Number
- NCT07170475
- Locations
- 🇯🇵
Fujita Health University, Toyoake, Aichi-ken, Japan
Thrombus Aspiration and Pathology and OCT Study
Recruiting
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Fujita Health University
- Target Recruit Count
- 200
- Registration Number
- NCT07151976
- Locations
- 🇯🇵
Fujita Health University, Toyoake, Aichi-ken, Japan
CT-Angiography Plaque Characteristics and Events in Deferral Patients by Invasive Fractional Flow Reserve
Recruiting
- Conditions
- Patient Preference
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Fujita Health University
- Target Recruit Count
- 400
- Registration Number
- NCT06508697
- Locations
- 🇯🇵
Fujita Health University, Toyoake, Aichi, Japan
Safety and Immunogenicity of EXG-5003
Phase 1
Completed
- Conditions
- COVID-19
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Fujita Health University
- Target Recruit Count
- 40
- Registration Number
- NCT04863131
- Locations
- 🇯🇵
Fujita Health University Hospital, Toyoake, Aichi, Japan
Comparison Between OFDI and IVUS in PCI Guidance for Biolimus A9 Eluting Stent Implantation
Phase 2
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Fujita Health University
- Target Recruit Count
- 96
- Registration Number
- NCT03292081
- Locations
- 🇯🇵
Fujita Health University, Toyoake, Japan
- Prev
- 1
- 2
- Next
News
Adipose-Derived Stem Cell Injections Show Promise in Treating Inflammatory Eye Diseases
Japanese researchers demonstrate that local injections of adipose-derived mesenchymal stem cells effectively reduce inflammation in ocular graft-versus-host disease, offering a safer alternative to corticosteroids.